Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04591717 · ClinicalTrials.gov registry record · Phase 1
COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers
A Phase 1 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT04591717 is a Phase 1 study that has completed, run by ImmunityBio. The registered enrollment target is 34 participants.
The verdict
NCT04591717, a Phase 1 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
Interventions
- BIOLOGICAL hAd5-S-Fusion+N-ETSD vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04591717
The ClinicalTrials.gov registry entry for NCT04591717 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmunityBio, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hAd5-S-Fusion+N-ETSD vaccine is the first listed.
NCT04591717 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04591717 about?
NCT04591717 is a clinical study titled "COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers". This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity of the hAd5-S-Fusion+N-ETSD vaccine and select a dose for future studies.
What is the current status of trial NCT04591717?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2020-10-19. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT04591717?
The interventions under investigation include: hAd5-S-Fusion+N-ETSD vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT04591717?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.